Lund University Hospital

This study tests whether adding a third chemotherapy drug (irinotecan) to the standard two-drug regimen before and after surgery can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 60 adults with early-stage, operable cancer will rec…